Search Results for 'license'
-
Biologics, Proteins, Vaccines | Breaking News | Industry News | Scale-up/Technology Transfer
SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax
Will leverage SUREtechnology Platform to generate stable, high-yield production cell lines needed for human clinical trials.Kristin Brooks 03.18.21
-
APIs | Breaking News | Formulation Development | Industry News
Tris Pharma, Athena Bioscience Enter Exclusive License Agreement
Athena gains exclusive rights to commercialize a long-acting antihypertensive product developed using Tris' proprietary technology.Kristin Brooks 02.22.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
AbbVie Licenses ProBioGen’s GlymaxX Technology
Will apply GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).Kristin Brooks 01.22.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Biogen Licenses CEVEC AAV Mfg. Technology
Biogen gains rights to ELEVECTA Technology for manufacturing of gene therapy products.Contract Pharma Staff 01.08.21
-
Breaking News | Collaborations & Alliances | Industry News
Lead Pharma and Roche Enter Collaboration & License Agreement
Will develop oral small molecules to treat immune mediated diseases.Contract Pharma Staff 11.16.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
CEVEC, Roche Ink ELEVECTA Technology License Agreement
Allows Roche to use CEVEC's ELEVECT Technology for AAV vector manufacturing for its portfolio of gene therapy products.Contract Pharma Staff 11.11.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
CEVEC, Rznomics Ink License Agreement for CAP Technology
Rznomics will use CEVEC’s cell line technology with its trans-splicing ribozyme technology for manufacturing gene therapies targeting various cancers.10.20.20
-
Breaking News | Collaborations & Alliances | Drug Development
Sperogenix and Minoryx Enter Exclusive License Agreement
Will develop and commercialize leriglitazone in mainland China, Hong Kong and Macau.Contract Pharma Staff 09.23.20
-
Breaking News | Clinical Trials
Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo
DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.Contract Pharma Staff 09.02.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
iBio Signs License Agreement with Planet Biotechnology for COVID-19 Therapeutic
ACE2-Fc directly targets coronavirus virions.Contract Pharma Staff 09.01.20
-
Breaking News | Drug Development | Industry News
Ovid, Angelini Pharma Enter Exclusive License Agreement
To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in EuropeContract Pharma Staff 07.13.20
-
Breaking News | Drug Development | Industry News
Oncology Venture Out-Licenses Clinical Assets to Smerud
Smerud will advance development of LiPlaCis in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme.Contract Pharma Staff 06.29.20
-
Breaking News | Collaborations & Alliances | Drug Development
Neurocrine Licenses Seven Takeda Compounds in $2B Deal
To develop and commercialize early-to-mid-stage psychiatry pipeline including assets for for schizophrenia, treatment-resistant depression and anhedonia.Contract Pharma Staff 06.19.20
-
Breaking News | Industry News
Wasdell Group Receives IMP License for European HQ
Enables Wasdell to expand the facility’s services.Contract Pharma Staff 05.29.20
-
Formulation Development | Industry News
SeraNovo, Carna Biosciences Enter Second License Agreement
To develop an oral formulation of a new active ingredient with enhanced bioavailability.Contract Pharma Staff 05.26.20
-
Breaking News | Industry News
Gilead, Mylan Ink Global Remdesivir License Agreement
To supply Remdesivir for potential COVID-19 treatment in 127 low- and middle-income countries.Contract Pharma Staff 05.12.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Industry News
Fujifilm Diosynth Licenses Oxgene's AAV system
Aims to deliver gene therapy products to clients with an approximate 25% lead-time reductionContract Pharma Staff 04.23.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
panCELLa, CCRM Collaborate to Benefit Academia and Industry
New iPSC master cell banks to accelerate development of novel cell therapiesContract Pharma Staff 04.21.20
-
Breaking News | Collaborations & Alliances | Drug Delivery | Industry News | Injectables
Micropore, InnoCore Enter Injectable Drugs Collaboration
Will deploy encapsulation technology in the production of a new generation of long acting injectablesContract Pharma Staff 04.21.20
-
New iPSC Master Cell Banks to Accelerate Development of Novel Cell Therapies
panCELLa and CCRM collaborate to benefit academia and industry
-
Breaking News | Promotions & Moves
ADC Therapeutics Appoints Jennifer Creel as CFO
Former Celgene executive brings deep oncology-focused financial expertiseContract Pharma Staff 04.21.20
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Soligenix Licenses BTG’s CoVaccine HT for SARS-CoV-2
Novel adjuvant has been shown to enhance both cell-mediated and antibody-mediated immunityContract Pharma Staff 04.16.20
-
Breaking News | Drug Development | Trials & Filings
Regeneron's BLA for Ebola Cocktail Gets Priority Review
VelociSuite technologies facilitate rapid generation of optimized antibodies allowing for cell line production and large-scale bioreactor manufacturingContract Pharma Staff 04.16.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
AIkido Pharma Inks Exclusive License for Antiviral Drug Platform
Pan-viral inhibitory compound with efficacy against multiple viral pathogens including Influenza, SARS-COV, MERS-COV, Ebola and Marburg virusContract Pharma Satff 04.14.20
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
Arrakis, Roche Ink Multi-Billion Dollar Deal to Develop RNA-based Therapies
Multi-target program to utilize RNA-targeted small molecule drug discovery platformContract Pharma Staff 04.09.20
-
Breaking News | Collaborations & Alliances | Drug Development
Amgen, Adaptive Biotech Enter COVID-19 Antibody Alliance
Aims to accelerate the development of a potential antibody against COVID-19 as fast as possible04.02.20
-
Breaking News | Collaborations & Alliances | Industry News
Citius, Novellus Ink COVID-19 Pact
Citius to license novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-1904.01.20
-
Breaking News | Collaborations & Alliances | Drug Development
I-Mab, Kalbe Genexine Enter Strategic Pact
KG Bio will have option for exclusive rights to commercialize two I-Mab product candidates.03.31.20
-
Breaking News | Collaborations & Alliances | Drug Development
Lilly, Sitryx Enter Autoimmune Alliance
To develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.03.31.20
-
Bio News | Biosimilars | Breaking News | Collaborations & Alliances | Industry News
Alvotech, DKSH Partner to Bring Biosimilar to Asia
Biosimilar of AbbVie’s Humira to be developed and supplied by Alvotech03.26.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development
Akers Biosciences Licenses Premas Coronavirus Vax Candidate
Aims to accelerate development timeline leveraging the D-Crypt platform03.25.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
Debiopharm Expands Its Radiopharmaceutical Footprint
Exclusive license and research agreement to further develop radioligand program to fight the progression of cancer.03.25.20
-
Breaking News | Collaborations & Alliances | Drug Development
Forge, Roche Enter Antibiotic Alliance
To develop novel antibiotic to treat serious lung infections attributed to antibiotic-resistant Gram-negative bacteria03.25.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Codexis, Takeda Sign Gene Therapy Collaboration
Partnership to leverage Codexis’ protein engineering platform to advance novel gene therapies for rare genetic disorders03.24.20
-
-
Breaking News | Collaborations & Alliances | Drug Delivery | Industry News
Hikma, Glenmark Enter Nasal Spray Tie-up
Builds on Hikma's leading position in nasal sprays02.28.20
-
Analytical Services | Breaking News | Industry News | Laboratory Testing
Pluton Biosciences Acquires Microbe Inotech Labs
MiL’s pathogen testing provides Pluton a foundation to build out Micro-mining microbial discovery platform02.20.20
-
Breaking News | Facilities | Industry News
Vetio Awarded Cannabis Research License from Health Canada
Begins development of cannabis-based veterinary drug products in Montreal02.19.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Excipients | Industry News
ReForm Biologics, MilliporeSigma Enter Excipient Agreement
Deal covers excipient development and commercialization02.10.20
-
Breaking News | Industry News | Inspections
-
Breaking News | Collaborations & Alliances | Drug Development
Avacta, Daewoong Partner with AffyXell Therapeutics
To utilize Affimer proteins in next generation cell and gene therapies02.03.20
-
Capacity Management Within Functional Service Partnerships
Looking at the advantages and disadvantages of moving capacity management from sponsors to their FSP vendors.Brian Ford and Timothy King, PPD FSP 01.28.20
-
Breaking News | Drug Development | Industry News
Sun Pharma, Rockwell Medical Enter Licensing and Supply Pact
Sun Pharma will be the exclusive development and commercialization partner for Rockwell's Triferic01.16.20
-
Breaking News | Industry News | Regulatory Affairs
Dalton Expands Cannabinoids Capabilities
Receives license amendment from Health Canada Cannabis Regulation approving sale of cGMP cannabis derived products to License Holders.01.15.20
-
Drug Development | Industry News
Oncologie Receives Exclusive Navicixizumab License
To develop and commercialize navicixizumab in advanced heavily pretreated ovarian cancer01.14.20
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
Astellas, Adaptimmune Enter CAR-T Alliance
Aims to develop new stem-cell derived allogeneic T-cell therapies to treat cancer01.14.20
-
Breaking News
Horizon Discovery Signs Collaboration and License Agreement With Mammoth Biosciences
Aims to develop the next generation of engineered CHO cell lines, to improve production of biotherapeutics.Horizon Discovery Group 01.13.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
ProBioGen Inks Commercial GlymaxX License with Roche
ADCC-enhancement for innovative cancer therapy.01.13.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Almirall, WuXi Biologics Ink Strategic Antibody Aliance
Aims to develop innovative biologics for dermatology diseases including atopic dermatitis01.10.20
-
Breaking News | Drug Development | Industry News
Immunic Exercises Option to License Daiichi’s IMU-856
Orally available, small molecule modulator targets an undisclosed protein and represents a new approach for the treatment of intestinal diseases01.08.20
